Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 1/2010

01-01-2010 | Drug and Profile Reports

Ferric carboxymaltose: a guide to its use in iron-deficiency anaemia

Published in: Drugs & Therapy Perspectives | Issue 1/2010

Login to get access

Excerpt

Ferric carboxymaltose, a novel iron complex that consists of a ferric hydroxide core stabilized by a carbohydrate shell, allows for controlled delivery of iron. Administered intravenously, it is effective in the treatment of iron-deficiency anaemia, delivering a replenishment dose of up to 1000 mg of iron (maximum dose 15 mg/kg bodyweight per week). Adapted from Drugs 2009; 69 (6): 739-56.[1] …
Literature
1.
Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009; 69(6): 739–56PubMedCrossRef
2.
Ferinject: UK summary of product characteristics. Purley: Syner-Med (Pharmaceutical Products) Ltd, 2009 Jul 9
3.
Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert 2009; 23(1): 11–6
4.
UK Medicines and Healthcare Products Regulatory Agency. Public assessment report (decentralised procedure): Ferinject 50mg iron/ml solution for injection/infusion (PL 15240/0002; UK/H/0894/001/DC) [online]. Available from URL: http://​www.​mhra.​gov.​uk [Accessed 2009 Oct 30]
5.
Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (Ferinject®) randomized controlled trial. Am J Gastroenterol 2008 May; 103(5): 1182–92PubMedCrossRef
6.
Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. Epub 2009 Jul 22
7.
Breymann C, Gliga F, Bejenariu C, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008 Apr; 101(1): 67–73PubMedCrossRef
8.
Seid MH, Derman RJ, Baker JB, et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008 Oct; 199(4): 435.e1–7CrossRef
9.
Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007 Aug; 110(2 Pt 1): 267–78PubMedCrossRef
10.
Qunibi WY, Martinez C, Smith M, et al. Efficacy and safety of IV ferric carboxymaltose (FCM) compared to oral iron in anemic patients with non-dialysis-dependent CKD [abstract no. MO0 17 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; Stockholm
11.
Schaefer RM, Khasabov NN, Todorov NG, et al. The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anaemia [abstract no. MP375 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; Stockholm
12.
Qunibi W, Dinh Q, Benjamin J. Safety and tolerability profile of ferric carboxymaltose (FCM): data from the FCM clinical program, [abstract no. MP383 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; Stockholm
13.
Seid MH, Mangione A, Valaoras TG, et al. Safety profile of iron carboxymaltose, a new high dose intravenous iron in patients with iron deficiency anemia [abstract no. 3739]. Blood 2006 Nov 2; 108(11 Pt 2): 8b
Metadata
Title
Ferric carboxymaltose: a guide to its use in iron-deficiency anaemia
Publication date
01-01-2010
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 1/2010
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.2165/11203350-000000000-00000

Other articles of this Issue 1/2010

Drugs & Therapy Perspectives 1/2010 Go to the issue

Drug Reactions and Interactions

First reports of serious adverse drug reactions in recent weeks

Disease Management

Worldwide control of trachoma involves a strategy combining surgery, antibacterials, facial cleanliness and environmental improvements

Disease Management

Aggressive treatment is essential to reduce cardiovascular risk in diabetic hypertensive patients

Drug and Profile Reports

Fesoterodine: a guide to its use in overactive bladder syndrome

Disease Management

Antidepressants are the main options for the long-term pharmacological treatment of generalized anxiety disorder

Drug Reactions and Interactions

Glitazones accelerate bone loss and increase the risk of fracture in patients with type 2 diabetes mellitus